Pure Extracts Submits Natural Health Product License


VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a herbal extraction company focused on cannabis, hemp, functional mushrooms and the booming psychedelic, is thrilled to announce that its wholly-owned subsidiary, Pure Mushrooms Corp., has submitted a licensing application to Health Canada’s Natural and Non-prescription Health Products Directorate for a wellness product based on of mixed functional mushrooms.

This app for a blend of cordyceps, reishi and lion’s mane follows the company’s successful launch on its Amazon online store selling its reishi and maitake formulations. These 2 products appeal to both men and women with 57% of purchases coming from men and 43% from women with the most sales made in California, followed by Florida and then Georgia.

The new blended formula provides antioxidants that help protect cells against oxidative damage caused by free radicals. It is also used in Herbal Medicine as a liver tonic, to support the immune system, and as an adaptogen to help increase energy and resistance to stress. The product launch is expected to take place in the fourth quarter of 2021.

Pure Extracts CEO Ben Nikolaevsky said, “We are excited to create our next Pure Mushrooms products for our direct-to-consumer online store. The functional mushroom wellness market is seeing robust sales as many consumers attempt to boost their immune systems in light of the COVID-19 pandemic. As we build our mushroom extraction facility, we plan to bring more products to market. »

Ben Nikolaevsky
Ben Nikolaevsky
CEO and Director

On Pure extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)
Pure Extracts Technology Corp. features a brand new state of the art processing facility located just 20 minutes north of the famous town of Whistler, BC. The bespoke facility was built to European Union GMP standards aimed at exporting products and formulations, including those currently restricted in Canada, to European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its standard processing license on September 25, 2020. The company’s shares began trading on the Canadian Securities Exchange (CSE) on November 5, 2020 .

Learn more at https://pureextractscorp.com/.

For more information:
Investor Relations Pure Extracts
Tel: +1 604 493 2052
[email protected]

Forward-looking statements
This press release contains forward-looking statements relating to the future operations of Pure Extracts, and other statements are not historical facts. Forward-looking statements are often identified by words such as “will”, “may”, “should”, “anticipate”, “expect” and similar expressions. All statements, other than statements of historical facts, included in this release, including, without limitation, statements regarding expansion into the United States and Pure Extracts’ future plans and objectives, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect and we cannot guarantee that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will be consistent with the Company’s expectations and projections is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update forward-looking information, except if and to the extent required by applicable securities laws.

This press release contains information about potential sales revenues from supply agreements, which may be considered financial outlook disclosure under applicable securities laws. This information is subject to the same assumptions, risk factors, limitations and qualifications as set out in the paragraph above. Specifically, the estimated sales revenues that may arise from supply contracts have been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. The financial outlook contained in this press release has been prepared by management as of the date of this press release and has been provided for the purpose of providing readers with an understanding of the potential revenues that may arise from the recently concluded supply agreement. by the Company and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for any purpose other than that for which it is disclosed herein.

The CSE has neither approved nor disapproved of the content of this press release.


Comments are closed.